Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: In November 2018, the “Weird Facts” Facebook page posted a widely-shared meme which outlined the death of Joyce Carol Vincent, summarizing it as “In 2006, a woman (Joyce Carol Vincent) was found in her London flat, skeletonized, after 3 years of being dead — with the TV still running”:  Notwithstanding the somewhat crass imagery used in the meme, this was unfortunately a largely accurate description of the tragic circumstances surrounding the death of Joyce Carol Vincent, who did indeed remain undiscovered at home for around two years, dying around December 2003. According to material prepared for release to the news media by the Metropolitan Police, as well as reports by the BBC and the Press Association, the following are the known facts surrounding Vincent’s demise. Some readers might find the details disturbing. On 26 January 2006, Vincent’s remains were discovered at her apartment in Wood Green, north-east London. Workers from the Metropolitan Housing Trust, an organization which provides affordable housing and is now known as Metropolitan Thames Valley, had forced entry while attempting to inquire about thousands of pounds of unpaid rent arrears. Vincent had been placed in the small apartment as part of a scheme for victims of domestic violence. Vincent’s remains were badly decomposed, and pathologist Dr. Simon Poole later described them as being “largely skeletal,” which supports the claim made in the “Weird Facts” meme. According to evidence heard at a coroner’s inquest, Vincent was found lying on her back on the floor of her living room next to a shopping bag and Christmas presents which she had wrapped but never delivered. Her television was indeed still switched on when Vincent was found. She was identified by reference to dental records. Based on the expiration dates of food and medication found in Vincent’s flat, it was estimated that she had died around December 2003, some two years earlier — not three years earlier, as the “Weird Facts” meme and several news reports mistakenly stated. She was born in London to Grenadian immigrant parents in 1965, and was 38 years old at the time of her death. In the years after Vincent was discovered, the filmmaker Carol Morley tracked down her friends, colleagues and associates. In interviews which would ultimately form the basis of the 2011 documentary film Dreams of a Life, those who knew Vincent universally recalled their shock and disbelief at the circumstances of her death and discovery. In the film some friends recounted actually having read news accounts of her death in April 2006, but without an accompanying photograph, they did not connect the horrific circumstances of her discovery with the person they had known. According to those accounts, Vincent had for many years been a very social, popular professional young woman who worked in London’s fast-paced financial district in the 1980s and 1990s, was highly intelligent and charming, and was remarkably attractive and frequently the object of male attention. Vincent, who was at one time an aspiring singer, was acquainted with the soul vocalist Betty Wright, and had dinner with other iconic musical artists, including Gil Scott-Heron, Jimmy Cliff, and Ben E. King. In 1990, Vincent briefly met and conversed with Nelson Mandela backstage at a concert in London’s Wembley Stadium. Although she had many friends, Vincent’s friendships appear to have been somewhat fleeting, and despite the deep affection in which she was held, she was known for “drifting” in and out of social groups and relationships and sometimes appeared troubled. Her acquaintances recalled that she was distant towards her family members. According to Morley’s interviews with friends of Vincent, she became engaged to marry an unidentified man in the late 1990s, and the Metropolitan Police later noted that she had been involved in a “domestic incident” in 1998. In Morley’s documentary, Vincent’s friends observed that she was likely to have been in at least one abusive relationship during that time. By 2001, Vincent left her job at the accounting firm Ernst & Young and progressively lost contact with her family members, friends and former colleagues, working for a time as a cleaner. She changed addresses frequently but moved into her final apartment in Wood Green in February 2003, having been placed there as part of a women’s refuge program for victims of domestic violence. Her friends have speculated that she may have become isolated and withdrawn over time because she was ashamed of the abuse she had suffered and the shift in her professional and personal circumstances, and she may also have been avoiding detection by an abusive former partner. In November 2003, she was briefly hospitalized after vomiting blood and was diagnosed with a peptic ulcer. Although she is believed to have died around a month later, the coroner was unable to arrive at a cause of death due to the decomposition of her remains by January 2006. She also suffered from asthma, which was cited by her friends as a possible cause of death.
[A]: In 2006, the skeletal remains of Joyce Carol Vincent were found in her home, with the television on, years after her death. 


[Q]: The company’s forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain’s second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca’s sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his “more constructive thesis” for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon’s Savvas Neophytou remains more wary, pointing out that Soriot’s predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca’s longer-term prospects. “In our view, management is stepping onto thin ice with this same sort of guidance,” Neophytou said, pointing out the previous management’s failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb’s share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts’ revenue forecasts significantly, suggesting that a more realistic “adjusted consensus” for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company’s thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body’s immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients’ lives significantly and generate tens of billions of dollars in annual sales.
[A]: Drugmaker AstraZeneca forecasts faster return to growth.


[Q]: North Korean leader Kim Jong Un vowed to work toward denuclearization at a landmark summit with U.S. President Donald Trump in Singapore in June but the two sides have made little progress. North Korea raised new doubts about a nuclear agreement on Thursday when its state media said any deal on it giving up its nuclear arsenal had to include the complete elimination of U.S. “nuclear threats”. While the United States and North Korea joust over a nuclear deal, South Korea is keen to improve ties with its old rival and has been taking steps to establish links in various areas including transport and humanitarian assistance. There has been some U.S. concern that the South may be moving too quickly on building such links, given the scant progress on denuclearization. Despite that, Stephen Biegun, the U.S. special representative for North Korea, said on Wednesday as he arrived in South Korea for talks that he would be looking with aid groups at how to deliver “appropriate assistance” to the North, particularly in the winter. South Korea’s special representative for Korean peace and security affairs, Lee Do-hoon, said after talks with Biegun on Thursday the United States agreed to help supply the North with the flu drug Tamiflu. “The issue of providing Tamiflu to the North Korean people was resolved,” Lee told reporters. South Korea provided 500,000 doses of Tamiflu to the North in 2009 following an outbreak of H1N1 influenza. The Red Cross said in January this year that more than 81,000 North Koreans were affected by the same virus also known as swine flu. Humanitarian aid is not subject to tough sanctions on North Korea aimed at pressing it to give up its nuclear weapons and ballistic missile programs. But officials at U.N. agencies and aid groups have told Reuters that their operations have nearly ground to a halt because of the strict interpretation of U.N. curbs on banking and shipping to North Korea, as well as a travel ban for U.S. citizens. Lee said he had secured U.S. sanctions exemptions over a plan to reconnect rail and road links, as well as the joint excavation of remains of soldiers killed in the 1950-53 Korean War in the Demilitarised Zone, which is administered by the U.S.-led United Nations Command. Biegun said while the United States had no intention of easing sanctions, such cooperation could help advance the nuclear diplomacy. “Of course, all of this is intended to advance what we’re trying to do with North Korea,” Biegun told reporters. “Now that work begins with denuclearization but also includes the strong commitments by both of our countries to transform relations and build a permanent peace regime on the Korean peninsula,” he said. Trump has said a second summit with Kim was likely in January or February, though he wrote on Twitter last week that he was “in no hurry”. Biegun said the United States and North Korea had yet to agree on a date or venue for a second summit, but would work for an “agreeable outcome”. “We’re eager to move to the next stage of discussions with our North Korean partners,” he said.
[A]:
U.S. to help South Korea get flu drugs to North despite stalled nuclear talks.